GWHP logo

Global WholeHealth Partners Corporation (GWHP) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Global WholeHealth Partners Corporation (GWHP) es una empresa del sector Healthcare valorada en 0. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 15 mar 2026
Puntuación de IA de 43/100

Global WholeHealth Partners Corporation (GWHP) Resumen de Asistencia Médica y Tuberías

CEOEdgar B. Gonzalez
Sede CentralSan Clemente, US
Año de la oferta pública inicial (OPI)2015

Global WholeHealth Partners Corporation develops and markets in-vitro diagnostic test kits, including rapid tests for diseases like Ebola, Zika, and COVID-19, targeting both consumer and point-of-care markets in the United States. With a focus on rapid diagnostics, the company operates in a competitive landscape of medical diagnostics and research.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 15 mar 2026

Tesis de Inversión

Global WholeHealth Partners Corporation operates in the medical diagnostics sector, focusing on rapid in-vitro diagnostic test kits. The company's negative profit margin of -69898.3% and gross margin of -1518.6% indicate significant challenges in achieving profitability. Growth catalysts may include expanding the range of diagnostic tests offered and increasing market penetration in point-of-care settings. However, the company's negative beta of -11.47 suggests an inverse correlation with the market, which could be a risk factor. The lack of a dividend yield may deter some investors. The company's success hinges on achieving profitability and effectively marketing its diagnostic solutions.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.00B indicates a small company with limited financial resources.
  • P/E ratio of -0.00 reflects the company's current lack of profitability.
  • Profit Margin of -69898.3% indicates substantial losses and operational inefficiencies.
  • Gross Margin of -1518.6% suggests that the cost of goods sold significantly exceeds revenue.
  • Beta of -11.47 indicates an inverse correlation with the market, meaning the stock may move in the opposite direction of the overall market.

Competidores y Pares

Fortalezas

  • Focus on rapid diagnostic tests.
  • Offers tests for both consumer and point-of-care use.
  • Provides tests for a range of infectious diseases.

Debilidades

  • Negative profit margin indicates financial instability.
  • Limited market capitalization restricts growth potential.
  • High dependence on specific diagnostic tests.

Catalizadores

  • Upcoming: Potential partnerships with healthcare providers to expand market reach.
  • Ongoing: Development of new diagnostic tests for emerging infectious diseases.
  • Ongoing: Increasing sales of existing diagnostic tests in point-of-care settings.

Riesgos

  • Potential: Intense competition in the medical diagnostics industry.
  • Potential: Regulatory changes affecting diagnostic test approval.
  • Ongoing: Negative profit margin and gross margin indicate financial instability.
  • Ongoing: Limited market capitalization restricts growth potential.

Oportunidades de crecimiento

  • Expanding the range of diagnostic tests offered: Global WholeHealth Partners Corporation can expand its product line to include tests for a broader range of diseases and conditions. This could involve developing new tests in-house or acquiring existing tests from other companies. The market for diagnostic tests is estimated to reach $100 billion by 2028, presenting a significant opportunity for growth. Timeline: Ongoing.
  • Increasing market penetration in point-of-care settings: The company can focus on increasing its presence in hospitals, physicians' offices, and medical clinics. This could involve partnering with healthcare providers to offer its diagnostic tests as part of their standard of care. The point-of-care diagnostics market is expected to grow at a CAGR of 8% over the next five years. Timeline: Ongoing.
  • Developing tests for over-the-counter consumer use: Global WholeHealth Partners Corporation can develop and market diagnostic tests that can be used by consumers at home. This could involve creating easy-to-use tests for common conditions such as influenza and strep throat. The market for over-the-counter diagnostic tests is growing rapidly, driven by the increasing demand for convenient and accessible healthcare solutions. Timeline: Ongoing.
  • Expanding into new geographic markets: The company can expand its operations into new geographic markets, such as Europe and Asia. This could involve establishing partnerships with local distributors or setting up its own sales and marketing operations. The global market for diagnostic tests is expected to reach $100 billion by 2028, with significant growth opportunities in emerging markets. Timeline: Ongoing.
  • Leveraging strategic partnerships: Global WholeHealth Partners Corporation can form strategic partnerships with other companies in the healthcare industry, such as pharmaceutical companies and medical device manufacturers. These partnerships could help the company to expand its product line, increase its market reach, and access new technologies. Strategic partnerships can provide access to new markets and technologies, accelerating growth. Timeline: Ongoing.

Oportunidades

  • Expanding the range of diagnostic tests offered.
  • Increasing market penetration in point-of-care settings.
  • Developing tests for over-the-counter consumer use.
  • Expanding into new geographic markets.

Amenazas

  • Intense competition in the medical diagnostics industry.
  • Regulatory changes affecting diagnostic test approval.
  • Economic downturn impacting healthcare spending.

Ventajas competitivas

  • Focus on rapid diagnostic tests provides a competitive advantage in time-sensitive situations.
  • Proprietary in-vitro diagnostic test kits offer differentiation.
  • Established relationships with hospitals and clinics provide a distribution channel.

Acerca de GWHP

Global WholeHealth Partners Corporation, incorporated in 2013 and based in San Clemente, California, focuses on developing and marketing in-vitro diagnostic test kits within the United States. The company's product line includes rapid diagnostic tests designed for the detection of various diseases, such as COVID-19, Ebola, Zika, dengue, malaria, influenza, and tuberculosis. These tests are intended for use in over-the-counter consumer settings, as well as point-of-care environments, including hospitals, physicians' offices, and medical clinics. The company aims to provide accessible and rapid diagnostic solutions for a range of infectious diseases. By offering tests for both consumer and professional use, Global WholeHealth Partners Corporation seeks to address the growing need for timely and accurate disease detection. The company's focus on rapid diagnostics positions it within the broader medical diagnostics and research industry, where innovation and speed are critical factors for success. Global WholeHealth Partners Corporation continues to develop and market diagnostic solutions to meet the evolving needs of the healthcare market.

Qué hacen

  • Develops in-vitro diagnostic test kits.
  • Markets rapid diagnostic tests for diseases like COVID-19, Ebola, and Zika.
  • Offers tests for over-the-counter consumer use.
  • Provides tests for point-of-care settings such as hospitals and clinics.
  • Focuses on rapid detection of infectious diseases.
  • Offers diagnostic solutions for various vector-borne diseases.

Modelo de Negocio

  • Develops and manufactures in-vitro diagnostic test kits.
  • Sells diagnostic tests to hospitals, clinics, and consumers.
  • Generates revenue through direct sales and distribution agreements.

Contexto de la Industria

Global WholeHealth Partners Corporation operates within the medical diagnostics and research industry, a sector characterized by constant innovation and regulatory oversight. The market is driven by the increasing prevalence of infectious diseases and the demand for rapid and accurate diagnostic solutions. Competitors include companies like EPRSQ (Epsilon Advanced Materials), GNRS (Genrus Biotech International, Inc.), MICRD (Micron Solutions, Inc.), MLTO (Melotto, Inc.), and MTEM (Molecular Templates, Inc.). The company's success depends on its ability to develop and market innovative diagnostic tests that meet the evolving needs of healthcare providers and consumers.

Clientes Clave

  • Hospitals and medical clinics
  • Physicians' offices
  • Consumers seeking over-the-counter diagnostic tests
Confianza de la IA: 79% Actualizado: 15 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Global WholeHealth Partners Corporation (GWHP): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para GWHP.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GWHP.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para GWHP.

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de GWHP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Edgar B. Gonzalez

CEO

Edgar B. Gonzalez serves as the Chief Executive Officer of Global WholeHealth Partners Corporation. His background includes experience in the healthcare and diagnostics industries, with a focus on strategic leadership and business development. He has been involved in the development and marketing of in-vitro diagnostic test kits, contributing to the company's efforts to provide rapid diagnostic solutions for various diseases. His expertise lies in driving growth and innovation within the healthcare sector.

Historial: Under Edgar B. Gonzalez's leadership, Global WholeHealth Partners Corporation has focused on expanding its product line of rapid diagnostic tests and increasing its market presence in the United States. Key milestones include the development and launch of diagnostic tests for diseases such as COVID-19, Ebola, and Zika. His strategic decisions have aimed to position the company as a provider of accessible and rapid diagnostic solutions.

Información del mercado OTC de GWHP

The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC stock, GWHP may experience limited trading volume and wider bid-ask spreads compared to stocks listed on major exchanges. This can make it difficult for investors to buy or sell shares quickly and at a desired price. The potential for price volatility is higher due to the lower liquidity, which can impact investment returns.
Factores de riesgo OTC:
  • Limited financial disclosure increases the risk of investing in GWHP.
  • Lower trading volume and wider bid-ask spreads can lead to price volatility.
  • OTC Other tier status indicates a higher degree of risk compared to major exchanges.
  • Potential for limited regulatory oversight and transparency.
  • Dependence on a limited number of diagnostic tests.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings.
  • Assess the company's management team and their track record.
  • Evaluate the company's business model and competitive landscape.
  • Review the company's legal and regulatory compliance.
  • Analyze the company's cash flow and debt levels.
  • Check for any history of fraud or misconduct.
  • Confirm the company's contact information and physical address.
Señales de legitimidad:
  • Development and marketing of in-vitro diagnostic test kits.
  • Focus on rapid diagnostic tests for various diseases.
  • Targeting both consumer and point-of-care markets.

GWHP Preguntas Frecuentes sobre Acciones de Healthcare

¿Cuáles son los factores clave para evaluar GWHP?

Global WholeHealth Partners Corporation (GWHP) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Focus on rapid diagnostic tests.. Riesgo principal a monitorear: Potential: Intense competition in the medical diagnostics industry.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de GWHP?

GWHP actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de GWHP?

Los precios de GWHP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre GWHP?

La cobertura de analistas para GWHP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en GWHP?

Las categorías de riesgo para GWHP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition in the medical diagnostics industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de GWHP?

La relación P/E para GWHP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está GWHP sobrevalorada o infravalorada?

Determinar si Global WholeHealth Partners Corporation (GWHP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de GWHP?

Global WholeHealth Partners Corporation (GWHP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data is based on the most recent available information.
  • OTC market data may be limited or delayed.
Fuentes de datos

Popular Stocks